Trevi Therapeutics jumps on the biotech IPO train

Trevi Therapeutics jumps on the biotech IPO train

Source: 
Fierce Biotech
snippet: 

The eight-year-old New Haven, Connecticut-based company is focused on a series of diseases including chronic pruritus (severe itching), chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease.